An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
Peptides are inching closer to the mainstream. A panel of experts on Thursday narrowly recommended that the Food and Drug Administration reclassify four popular peptides—including one endorsed by podcaster Joe Rogan—to allow certain pharmacies to legally dispense them.
Reported by 2 outlets — WIRED, TIME. See all sources ↓
Peptides are inching closer to the mainstream. A panel of experts on Thursday narrowly recommended that the Food and Drug Administration reclassify four popular peptides—including one endorsed by podcaster Joe Rogan—to allow certain pharmacies to legally dispense them. In an at-times emotionally charged meeting that lasted more than 11 hours, members of an FDA advisory committee heard data presentations from FDA staff on four unapproved peptides—BPC-157, KPV, TB-500, and MOTs-C—as well as testimony from health care practitioners, patients, pharmacies, and clinics. Members voted eight to six, with one abstention, to add three of the four peptides to the agency’s bulks list, meaning compounding pharmacies can use them to create custom medications for patients.
Read the full report at WIRED ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- Peptides are inching closer to the mainstream. A panel of experts on Thursday narrowly recommended that the Food and Drug Administration reclassify four popular peptides—including one endorsed by podcaster Joe Rogan—to allow certain pharmacies to legally dispense them.
- How widely is it covered?
- 2 outlets, average source rating 7.0/10.
- When was it last updated?
- 7m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card2 outlets1CoverageScouting report
An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
Sources2TypeCoverageWIRED
TIME